Welcome message
Steatotic Liver Disease (SLD)—encompassing conditions from Metabolic dysfunction-associated SLD (MASLD) to Alcohol-associated Liver Disease (ALD), and their intersection (MetALD)—has emerged as the leading cause of liver disease worldwide. This rapidly evolving and multidisciplinary field is driving innovation across hepatology, cardiometabolism, addiction medicine, and beyond.
We are delighted to welcome you to the EASL SLD Summit 2026 in Budapest, Hungary, where experts, researchers, and clinicians from across the globe will gather to explore cutting-edge developments in research, diagnostics, and treatment. Following the successful relaunch of the SLD Summit series in 2023 in Prague—aligned with the updated nomenclature—the 2026 edition returns to a city rich in hepatology history, where the 25th EASL International Liver Congress was held in 1990.
This year's Summit aims to go beyond isolated organ perspectives to offer a holistic understanding of SLD. We will examine the shifting epidemiology of SLD through the lens of lifestyle, environmental exposures, genetics, and social determinants of health. The program will highlight how these interrelated drivers influence disease progression and therapeutic decision-making.
In line with EASL’s mission, the Summit will foster meaningful dialogue across disciplines. Key opinion leaders, clinician-scientists, early-career investigators, allied health professionals, and patient advocates will come together to share knowledge and co-create solutions. Each session will conclude with a Panel Discussion, encouraging synthesis, debate, and collaboration among speakers, chairs, and attendees.
Whether you are looking to energise your research, refine your clinical practice, or expand your understanding of this complex disease spectrum, the EASL SLD Summit 2026 offers a unique opportunity to stay at the forefront of the field.
Explore the full scientific program and join us in Budapest for the world's premier event dedicated to Steatotic Liver Disease.
We look forward to welcoming you!
Warm regards,
The EASL SLD Summit 2026 Organisers
EASL SLD Summit 2025 - Organising Committee
William Alazawi
United Kingdom
Read the bio
William Alazawi is Professor of Hepatology at Queen Mary University London and Consultant Hepatologist at The Royal London Hospital where he leads the steatotic liver disease clinical programme. He leads a thriving translational and clinical research group which studies the mechanisms of and potential treatments for steatotic liver disease.
Anna Alisi
Italy
Read the bio
Anna Alisi (MBio, PhD) completed her Biological Degree in 1998 at La Sapienza University of Rome in Italy, where she also obtained her PhD in Cellular and Developmental Biology and a Master’s in Bioinformatics. In July 2014, she obtained her specialisation in Clinical Pathology at Tor Vergata University of Rome in Italy.
In 2002, she obtained a research fellowship at Fondazione Francesco Balsano, where she is currently a member of the Scientific Committee. Subsequently, in 2007, she obtained a research contract at the Liver Unit of Bambino Gesù Children’s Hospital of Rome (Italy), where she currently serves as the Chief of the Research Unit of Genetics of Complex Phenotypes.
She is a member of several national and international scientific societies (EASL, ESPGHAN, AISF, SIBBM, IBMAI). In particular, she is a member of the special interest group on Steatotic Liver Diseases of ESPGHAN and a member of the special interest group on Artificial Intelligence of AISF.
From 1998, her research has focused on the field of liver cell physiology and pathogenetic mechanisms involved in several liver diseases (HCC, HCV and MASLD). The primary focus of her Unit in the last decade was translational research and interdisciplinary approaches to find MASLD diagnostic and prognostic biomarkers.
She has published about 270 peer-reviewed scientific papers and is the PI of several national and international grants about MASLD.
Ramon Bataller
Spain
Read the bio
Ramon Bataller graduated in Medicine from University of Valencia, Spain, and completed his residency and fellowship in Hepatology at Hospital Clinic in Barcelona. His PhD was on the role of Angiotensin in Liver Fibrosis after which he did a research fellowship at the University of North Carolina at Chapel Hill. For the past five years he worked as the Head of Hepatology in the University of Pittsburgh and has recently moved to take up the Chair of the Liver Unit at Hospital Clinic in Barcelona. His main interest is alcohol-induced liver disease and has focused his research on determinants of patient’s outcome and multi-OMICs studies in human samples to identify novel targets for therapy.
Cyrielle Caussy (EASL Governing Board representative)
France
Read the bio
Cyrielle Caussy (MD, PhD) is a full Professor of Medicine in Nutrition and an endocrinologist-diabetologist in the department of endocrinology, diabetes and nutrition, Lyon South Hospital Hospices Civils de Lyon and Lyon 1 University in France. She is also a researcher at CarMen laboratory (Cardio-Metabolism, Diabetes and Nutrition) INSERM U1060. She completed her MD training in 2013 and her PhD in Biochemistry at Lyon 1 University in 2015. Following her fellowship, she completed a 2-year advanced research training at the NAFLD Research Center, University of California at San Diego directed by Pr R. Loomba (2016-2018).
Her academic interests are in metabolic diseases including Type 2 Diabetes, Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). She leads a clinical and translational research program focusing non-invasive biomarkers and pathophysiology of MALSD at the Lyon Hepatology Institute. She co-leads the national AFEF/SFD Liver and Diabetes study group since 2023 and is a member of European Association for the Study of Liver Disease Scientific Committee since 2024.